Quick Answer
Enliven Therapeutics, Inc. reported Operating Income Loss of -$119.66 million for the year ending 2025.
- Enliven Therapeutics, Inc. showed a decrease of -14.4% in Operating Income Loss from 2024 to 2025.
- This data is from Enliven Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Enliven Therapeutics, Inc.'s Operating Income Loss has declined by 396.2%.
- Historical annual values: Fiscal year 2025: -$119.66 million | Fiscal year 2024: -$104.55 million | Fiscal year 2023: -$83.53 million | Fiscal year 2022: -$38.79 million | Fiscal year 2021: -$51.44 million | Fiscal year 2020: -$41.70 million | Fiscal year 2019: -$24.12 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: